MA38183A1 - Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase - Google Patents
Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinaseInfo
- Publication number
- MA38183A1 MA38183A1 MA38183A MA38183A MA38183A1 MA 38183 A1 MA38183 A1 MA 38183A1 MA 38183 A MA38183 A MA 38183A MA 38183 A MA38183 A MA 38183A MA 38183 A1 MA38183 A1 MA 38183A1
- Authority
- MA
- Morocco
- Prior art keywords
- relates
- btk
- compounds
- inhibitors
- kinase inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés qui forment des liaisons covalentes avec la tyrosine kinase de bruton (btk). L'invention concerne également des inhibiteurs irréversibles de btk. De plus, l'invention concerne également des inhibiteurs réversibles de btk. L'invention concerne également des compositions pharmaceutiques qui comprennent les composés. L'invention concerne des procédés d'utilisation des inhibiteurs de btk, seuls en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies auto-immunes ou d'états auto-immuns, de maladies hétéro-immunes ou d'états hétéro-immuns, le cancer, comprenant un lymphome, et des maladies ou états inflammatoires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727031P | 2012-11-15 | 2012-11-15 | |
| PCT/US2013/070164 WO2014078578A1 (fr) | 2012-11-15 | 2013-11-14 | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38183A1 true MA38183A1 (fr) | 2017-03-31 |
Family
ID=50728514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38183A MA38183A1 (fr) | 2012-11-15 | 2013-11-14 | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9096604B2 (fr) |
| EP (1) | EP2920180A4 (fr) |
| JP (1) | JP2015537033A (fr) |
| KR (1) | KR20150084923A (fr) |
| CN (1) | CN104854107A (fr) |
| AR (1) | AR093518A1 (fr) |
| AU (1) | AU2013344656A1 (fr) |
| BR (1) | BR112015011171A2 (fr) |
| CA (1) | CA2890934A1 (fr) |
| CL (1) | CL2015001268A1 (fr) |
| CR (1) | CR20150263A (fr) |
| DO (1) | DOP2015000108A (fr) |
| EA (1) | EA201590855A1 (fr) |
| HK (1) | HK1215253A1 (fr) |
| IL (1) | IL238728A0 (fr) |
| MA (1) | MA38183A1 (fr) |
| MX (1) | MX2015006168A (fr) |
| NI (1) | NI201500067A (fr) |
| PE (1) | PE20151495A1 (fr) |
| PH (1) | PH12015501067A1 (fr) |
| SG (1) | SG11201503842PA (fr) |
| TN (1) | TN2015000174A1 (fr) |
| TW (1) | TWI522359B (fr) |
| WO (1) | WO2014078578A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| WO2012158795A1 (fr) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Dérivés de pyrazolopyrimidine utilisés comme inhibiteurs de tyrosine kinase |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| DK2734205T3 (en) | 2011-07-21 | 2018-06-14 | Tolero Pharmaceuticals Inc | Heterocyclic Protein Kinase Inhibitors |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CA2920534A1 (fr) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methodes de traitement d'un cancer amplifie par her2 |
| CN105764896A (zh) | 2013-09-30 | 2016-07-13 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶的抑制剂 |
| RU2677884C2 (ru) | 2013-09-30 | 2019-01-22 | Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| CA2959602A1 (fr) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2017027883A1 (fr) * | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase |
| US10611766B2 (en) * | 2015-09-16 | 2020-04-07 | Loxo Oncology Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| CN106588937B (zh) * | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| CN106946896B (zh) * | 2017-03-30 | 2019-05-21 | 成都知普莱生物医药科技有限公司 | 呋喃并[2,3-d]嘧啶-4-胺衍生物 |
| IT201700099690A1 (it) * | 2017-09-06 | 2019-03-06 | Abiogen Pharma Spa | Composizione per l’integrazione di calcio |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
| WO2020142557A1 (fr) * | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibiteurs irréversibles de l'interaction ménine-mll |
| HUE072069T2 (hu) | 2019-02-12 | 2025-10-28 | Sumitomo Pharma America Inc | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája |
| MX2021009752A (es) * | 2019-02-15 | 2021-09-08 | Taiho Pharmaceutical Co Ltd | Derivado de 7h-pirrolo[2,3-d]pirimidin-4-amina. |
| CA3129665A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer |
| CN111825674A (zh) * | 2019-04-22 | 2020-10-27 | 上海仕谱生物科技有限公司 | 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 |
| US12312354B2 (en) | 2019-06-25 | 2025-05-27 | San Diego State University (Sdsu) Foundation | Selective BTK irreversible inhibitors |
| AU2020365951B2 (en) | 2019-10-14 | 2026-07-16 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| KR102993352B1 (ko) | 2019-12-20 | 2026-07-22 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태 |
| CA3168146A1 (fr) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Inhibiteurs therapeutiques de la tyrosine kinase pour la sclerose en plaques recurrente (rms) |
| WO2021150723A1 (fr) | 2020-01-22 | 2021-07-29 | Principia Biopharma Inc. | Formes cristallines de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényle) -1h-pyrazolo [3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4- (oxétane-3-yl)) pipérazine-1-yl] pent-2-enenitrile |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| WO2021185348A1 (fr) * | 2020-03-20 | 2021-09-23 | 深圳市塔吉瑞生物医药有限公司 | Dérivé d'acrylamide substitué et composition et utilisation associée |
| CN113527300B (zh) * | 2020-06-04 | 2023-02-03 | 广州百霆医药科技有限公司 | 布鲁顿酪氨酸蛋白激酶抑制剂 |
| US20250154154A1 (en) * | 2020-11-17 | 2025-05-15 | Relay Binney Street, 2nd Floor | Src inhibitors and uses thereof |
| CA3201936A1 (fr) | 2020-12-10 | 2022-06-16 | Minhua Chen | Forme cristalline de tolebrutinib et methode de preparation |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| WO2023078413A1 (fr) * | 2021-11-04 | 2023-05-11 | 微境生物医药科技(上海)有限公司 | Inhibiteur du fgfr2, son procédé de préparation et son utilisation pharmaceutique |
| US12016941B2 (en) * | 2022-03-03 | 2024-06-25 | Profounda Health And Beauty Inc. | Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms |
| AU2023372386A1 (en) | 2022-10-31 | 2025-05-08 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| AU3653099A (en) | 1998-04-17 | 1999-11-08 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
| US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| DE60014130T2 (de) | 1999-10-06 | 2006-03-09 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| AU4508601A (en) | 1999-11-30 | 2001-06-18 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
| WO2001044258A1 (fr) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Nouveaux heterocycles |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| EP1373554A2 (fr) | 2000-10-23 | 2004-01-02 | Bristol-Myers Squibb Company | Modulateurs de la tyrosine kinase de bruton, procedes pour leur identification, et leur utilisation |
| JP2004514732A (ja) | 2000-12-06 | 2004-05-20 | ファルマシア・コーポレーション | 迅速に分散する医薬組成物 |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
| WO2003000187A2 (fr) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation |
| EP2258371A1 (fr) | 2001-08-10 | 2010-12-08 | Novartis AG | Utilisation d'inhibiteurs c-Src seuls ou en combinaison avec STI571 pour le traitement de leucemies |
| WO2003016338A1 (fr) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Structure cristalline du domaine kinase de btk |
| WO2003046200A2 (fr) | 2001-11-21 | 2003-06-05 | Sunesis Pharmaceuticals, Inc. | Procedes de decouverte de ligands |
| US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
| GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
| JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| WO2005000197A2 (fr) | 2003-04-11 | 2005-01-06 | The Regents Of The University Of California | Inhibiteurs selectifs de la serine/threonine kinase |
| WO2004100868A2 (fr) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Procede servant a traiter le rejet d'un transplant |
| EP1473039A1 (fr) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| ES2372694T3 (es) | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| AU2005228845A1 (en) | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| WO2005074603A2 (fr) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Utilisation d'aminobenzoxazoles comme agents therapeutiques |
| MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| KR20070063562A (ko) | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | 치환 디피페리딘 ccr2 길항제 |
| JP2008519843A (ja) | 2004-11-10 | 2008-06-12 | シージーアイ ファーマスーティカル インコーポレーテッド | 特定のイミダゾ[1,2−a]ビラジン−8−イラミンズ、その生成方法及びそれに関する使用方法 |
| GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2006124462A2 (fr) | 2005-05-13 | 2006-11-23 | Irm, Llc | Composes et compositions convenant comme inhibiteurs de proteine kinase |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| WO2007058832A2 (fr) | 2005-11-12 | 2007-05-24 | Boehringer Ingelheim International Gmbh | INHIBITEURS DES KINASES Tec |
| KR20080098490A (ko) | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| WO2007089911A2 (fr) | 2006-01-30 | 2007-08-09 | The Scripps Research Institute | procedes de detection de cellules tumorales circulantes et procedes de diagnostic de cancer chez un sujet mammalien |
| KR20150038395A (ko) | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| US8604031B2 (en) | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP2529621B1 (fr) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
| WO2008054827A2 (fr) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation |
| NL2000640C2 (nl) | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2139487B1 (fr) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
| US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
| JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| JP5587193B2 (ja) | 2007-10-23 | 2014-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
| US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
| US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| JP2012501654A (ja) | 2008-09-05 | 2012-01-26 | アビラ セラピューティクス, インコーポレイテッド | 不可逆的インヒビターの設計のためのアルゴリズム |
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| ES2622138T3 (es) | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| AU2012255860C1 (en) * | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
| WO2015061752A1 (fr) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie |
| CN105949197A (zh) | 2014-01-29 | 2016-09-21 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
| WO2015127261A1 (fr) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarqueurs permettant de prédire la réponse du ldgcb à un traitement sous ibrutinib |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
-
2013
- 2013-11-14 KR KR1020157015148A patent/KR20150084923A/ko not_active Withdrawn
- 2013-11-14 SG SG11201503842PA patent/SG11201503842PA/en unknown
- 2013-11-14 EP EP13854424.2A patent/EP2920180A4/fr not_active Withdrawn
- 2013-11-14 WO PCT/US2013/070164 patent/WO2014078578A1/fr not_active Ceased
- 2013-11-14 CN CN201380059811.2A patent/CN104854107A/zh active Pending
- 2013-11-14 BR BR112015011171A patent/BR112015011171A2/pt not_active IP Right Cessation
- 2013-11-14 EA EA201590855A patent/EA201590855A1/ru unknown
- 2013-11-14 JP JP2015542791A patent/JP2015537033A/ja active Pending
- 2013-11-14 AU AU2013344656A patent/AU2013344656A1/en not_active Abandoned
- 2013-11-14 HK HK16103201.1A patent/HK1215253A1/zh unknown
- 2013-11-14 MX MX2015006168A patent/MX2015006168A/es unknown
- 2013-11-14 CA CA2890934A patent/CA2890934A1/fr not_active Abandoned
- 2013-11-14 MA MA38183A patent/MA38183A1/fr unknown
- 2013-11-14 PE PE2015000625A patent/PE20151495A1/es not_active Application Discontinuation
- 2013-11-15 TW TW102141817A patent/TWI522359B/zh not_active IP Right Cessation
- 2013-11-15 US US14/081,053 patent/US9096604B2/en active Active
- 2013-11-18 AR ARP130104233A patent/AR093518A1/es unknown
-
2015
- 2015-05-06 TN TNP2015000174A patent/TN2015000174A1/fr unknown
- 2015-05-08 US US14/708,099 patent/US9540385B2/en active Active
- 2015-05-10 IL IL238728A patent/IL238728A0/en unknown
- 2015-05-12 CL CL2015001268A patent/CL2015001268A1/es unknown
- 2015-05-12 DO DO2015000108A patent/DOP2015000108A/es unknown
- 2015-05-14 NI NI201500067A patent/NI201500067A/es unknown
- 2015-05-14 PH PH12015501067A patent/PH12015501067A1/en unknown
- 2015-05-19 CR CR20150263A patent/CR20150263A/es unknown
-
2016
- 2016-09-09 US US15/261,414 patent/US20160375026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215253A1 (zh) | 2016-08-19 |
| BR112015011171A2 (pt) | 2017-07-11 |
| CA2890934A1 (fr) | 2014-05-22 |
| IL238728A0 (en) | 2015-06-30 |
| PH12015501067A1 (en) | 2015-08-10 |
| DOP2015000108A (es) | 2015-06-30 |
| CR20150263A (es) | 2015-08-24 |
| CL2015001268A1 (es) | 2015-07-10 |
| AR093518A1 (es) | 2015-06-10 |
| SG11201503842PA (en) | 2015-06-29 |
| PE20151495A1 (es) | 2015-10-23 |
| AU2013344656A1 (en) | 2015-06-04 |
| EP2920180A4 (fr) | 2016-04-13 |
| TWI522359B (zh) | 2016-02-21 |
| TN2015000174A1 (en) | 2016-10-03 |
| US20160375026A1 (en) | 2016-12-29 |
| US20150239897A1 (en) | 2015-08-27 |
| TW201425315A (zh) | 2014-07-01 |
| US9540385B2 (en) | 2017-01-10 |
| NI201500067A (es) | 2016-02-15 |
| WO2014078578A1 (fr) | 2014-05-22 |
| MX2015006168A (es) | 2015-08-10 |
| US20140142126A1 (en) | 2014-05-22 |
| EP2920180A1 (fr) | 2015-09-23 |
| KR20150084923A (ko) | 2015-07-22 |
| CN104854107A (zh) | 2015-08-19 |
| EA201590855A1 (ru) | 2015-11-30 |
| US9096604B2 (en) | 2015-08-04 |
| JP2015537033A (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38961A1 (fr) | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose | |
| TN2015000168A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| TN2019000099A1 (fr) | Anticorps anti-lag-3 et compositions | |
| TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| EA201300246A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MA41654B2 (fr) | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton | |
| MA43094B1 (fr) | Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| MA34059B1 (fr) | Thérapie anti-angiogénique pour le traitement du cancer des ovaires | |
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| MA44909A (fr) | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk | |
| MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
| WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
| MA35064B1 (fr) | Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie | |
| MA38056A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA41643B1 (fr) | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton | |
| MA41065B1 (fr) | Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation |